Uncategorized

Women are losing sleep over this retirement savings fear

When it comes to retirement savings, living too long can be a blessing or a curse.

For women, who tend to outlive men and spend years caring for family members, it’s a major cause of anxiety. Those were the findings of a recent survey by the Nationwide Retirement Institute.

In February, the institute performed an online poll of 1,007 adults over age 50 with household income of at least $150,000 and 522 adults over age 50 who are or have been caregivers.

Of the participants, 71 percent of women said that they were worried about having enough money to pay for long-term care expenses.

Preparing for the future

Preparing for the future  10:08 AM ET Thu, 27 Sept 2018 | 01:08

That worry was especially keen among caregivers: 3 out of 4 said they were concerned about keeping up with long-term care costs.

Women feel the strain of long-term care keenly, as they tend to be the ones looking after their elderly and infirm parents and spouses.

“Sons want to care for mom and dad and be supportive, but they feel comfortable identifying an expert to navigate that,” said Joanna Gordon Martin, founder and CEO of Theia Senior Solutions.

“Daughters feel that it’s their responsibility to provide care, even if they don’t understand the complexity of the landscape,” she said.

Here’s what women need to know about planning for long-term care.

A slippery slope

It’s no secret that paying for long-term care is a costly endeavor. In 2017, the annual national median cost of bringing in a home health aide was $49,192, according to data from Genworth.

A year’s worth of care in a semiprivate room at a nursing home is even more: $85,775 was the annual national median cost, according to Genworth.

See below for details on assisted living expenses.

Assisted living costs across the nationThe cost of assisted living in 2016, by state.+-30k40k50k60k70kSource: Genworth Financial. Graphic: Nicholas Wells | CNBC. © Natural Earth

Colorado


Annual cost: $48,750
Rank: 15

Recruiting family members to help out with these needs adds on a different kind of cost.

Seven out of 10 of the participants in Nationwide’s study said they would like the option of relying on a family member if they needed long-term care.

Without the appropriate planning in place, things can quickly become overwhelming and may potentially endanger the caregiver’s career.

“It’s a slippery slope,” said Martin. “It starts with ‘I’ll go to one or two appointments’ and then it eventually becomes ‘I’ll fly down to Florida.'”

Indeed, on average, caregivers in Nationwide’s study said they spend 56 hours a week caring for loved ones.

The best laid plans

Caring for elderly patient

Peter Zander | Getty Images

Despite the fact that survey participants had a clear idea of how they wanted to be cared for, few people were talking to their family members about it.

About half of the individuals in the Nationwide study said they were speaking with their spouses about the cost of long-term care. Only 10 percent said they spoke with their kids about it.

“People want a family member to care for them, but they aren’t taking the steps to have the conversation,” said Holly Snyder, vice president of Nationwide’s life insurance business.

Here’s where to begin.

Talk to your spouse and the kids: You can’t prepare your family to provide care if you don’t make your wishes known well ahead of time. Work with your advisor and your family to discuss where and how to receive care, as those choices can be a significant factor in determining the cost.

Bring in your financial advisor: Your advisor can also help you come up with a way to pay for those expenses. Your funding choices for long-term care can include a traditional long-term care insurance policy, a hybrid cash-value life insurance policy to help cover these expenses or self-insuring with your own wealth — as long as you have the money.

Hammer out your legal documents: Head off legal battles at the pass. Get a health-care proxy in place so that you designate a trusted individual to oversee your medical care and ensure that professionals comply with your wishes in case you’re unable to communicate.

Also, consider a power of attorney for your finances. You would select a trusted person to make financial decisions for you and ensure your bills get paid if you’re incapacitated.

Don’t forget the small details: Imagine that your elderly parent has a medical emergency and is on the way to the hospital. Would you be able to answer questions on medications and allergies? Spell out those details in a written plan so that you’re ready.

“It’s not just the financials that are in play, but who are the doctors?” asked Martin. “What are the medications? Who will care for the dog? Have that plan in place.”

Preparing for a $6 Billion Market

Here’s How These Canadian Companies Are Preparing for Potential $6 Billion Market

The Canadian recreational cannabis market is one of the most exciting markets in the world. In summer 2018, Canada will become one of the first countries in the world to fully legalize recreational marijuana. Deloitte estimates the market to be a $4.98 – $8.78 Billion dollar opportunity, while a recent report says that in 2015 Canadians already spent $6.5 Billion on marijuana.

Big cannabis brands are taking opportunity very seriously and are moving quickly to prepare. Companies like Aphria Inc. (TSX: APH OTCQB: APHQF) and Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) are preparing by making strategic investments and purchases to bolster their rec presence.

The recreational market is such a huge opportunity that even big alcohol is getting in on it, with Constellation Brands (NYSE: STZ and STZ.B) recently investing $190 Million USD ($245 Million CDN) in Canopy Growth Corporation (TSX:WEED) (OTC: TWMJF).

These are examples of brands that specialize in medical marijuana trying to maximize and prepare for the recreational market as it blossoms. Of course the recreational market will demand different brands than medical.

For investors looking to capitalize on this huge opportunity, we’re following an emerging Canadian company with not one, but three major growing facilities under development and brand/distribution capacity that are perfectly built for the recreational market: MYM Nutraceuticals (CSE: MYM) (OTC: MYMMF).

We will look at MYM Nutraceuticals in a bit, but first let’s look at the recreational industry and what companies are doing to prepare.

Trends for 2018

After a crazy market upswing over Christmas and into the New Year, the Canadian Marijuana industry prepares for a big year.

Marijuana Index

Branding In The Canadian Recreational Industry

Advertising standards and regulations for the legalized marijuana industry are still being finalized, but just as with alcohol advertising, there will likely be very strict controls on advertising. Companies will have to be focused only on their own brand and adhere to ad standards of Canada.

This results in branding being one of the most important aspects of the new recreational industry.

Established companies were traditionally set up for medical and now have to somehow make the transition to market themselves for recreational use.

Key deals display the trend:

  • Aphria (TSX: APH OTCQB: APHQF) signed an agreement to acquire 100% of Broken Coast Cannabis, a premium cannabis producer located in British Columbia for $230 million in stock and cash. The deal will add incremental annual production of 10,500 kgs, some of that cannabis being market ready today. This addition will boost Aphria’s forecast annual production to 230,000 kgs. The transaction also gives Aphria more geographic diversification, a cross-Canada distribution platform, and access to over 40,000 medical patients.

 

  • Recent merger of DOJA Cannabis Company Limited (CSE: DOJA) and TS Brandco Holdings Inc. (“Tokyo Smoke”) created the first brand and retail-focused, Hiku, craft cannabis producer, with a portfolio of highly recognizable brands. Hiku is strategically positioned to become the preeminent cannabis brand house in the Canadian adult-use cannabis market. Concurrently, DOJA entered into a binding agreement with Aphria pursuant to which Aphria has committed to make a $10 million strategic equity investment into Hiku. Additionally, the parties have agreed on the terms of a supply agreement to secure cannabis concentrate supply for Hiku’s premium brand portfolio. Upon completion of the merger, the Company will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

 

  • Harvest One Cannabis  (TSXV:HVST) (OTC: HRVOF) through its wholly owned subsidiary United Greeneries announced the launch of retail sales beginning February 2018. Starting February 2018, United Greeneries will launch a new online retail platform for medical clients under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The initial offering will consist of two distinct cannabis brands, providing patients a wide range of different strains and cannabinoid profiles.

 

  • Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) has bought in 17% stake in The Green Organic Dutchman (TGOD), with option to Increase to in Excess of 50%.  As part of the agreement, the companies shall enter into a supply contract, providing Aurora with the right to purchase up to 20% of TGOD’s annual production of organic cannabis from TGOD’s Ancaster and Valleyfield facilities. Consequently, Aurora anticipates being able to procure in excess of 20,000 kg per annum of premium organic products once TGOD`s Valleyfield and Ancaster facilities are completed and at full capacity. The supply contract provides Aurora with the right to purchase up to 33% of TGOD’s production at the two facilities if Aurora increases its ownership interest to 31%.

 

  • Canada’s move toward legalization has already inspired one U.S. Company, the New York-based alcohol beverage producer Constellation Brands (NYSE: STZ and STZ.B), to buy a 10% stake in the Canadian pot company Canopy Growth Corporation (TSX:WEED) (OTC: TWMJF) for $190 million.

MYM Nutraceuticals (CSE: MYM) (OTC: MYMMF) – Ready to Rock The Rec Market

Unlike medical marijuana brands who have to acquire brands to prepare for rec, this small cap Canadian company was created with developing brands, marketing and distribution for the recreational market rom the get go.

MYM has also become a leading integrated provider of branded products related to the natural cannabis nutraceuticals industry. This strategy, coupled with its strategic partnerships, international expansion and growth in revenue have put MYM Nutraceuticals right in the sweet spot for rec.

Investors have already proven that they are excited about the MYM Nutraceuticals, with its share price experiencing over a 500% gain on the CSE since a momentum price rise in October 2017.

MYM Nutraceuticals has a video that explains their vision for the company.

Investment Highlights

MYM Nutraceuticals is a multi-faced, brand oriented marijuana company building the biggest growing operations and collaborations on the roster.

  • Through its subsidiary, Sublime Culture Inc., MYM Nutraceuticals is in the last stages of obtaining License Producer status under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).
  • MYM Nutraceuticals has taken a brilliant tact to assemble what, upon completion, will be the largest group of cannabis growing facilities in the world. The company has three projects that will bring its total growing capacity to over 625,000 square feet as early as 2019.
  • The projects include:
  • Weedon, Quebec: Its flagship project is a planned 1.5 million square foot growing facility in the town of Weedon, Quebec. Through its subsidiary, CannaCanada, the company is building what will be, at full capacity, the most productive Cannabis facility in the world by total output.
  • Laval Quebec: is a smaller by comparison, but will be MYM Nutraceuticals’ first operation to come online and begin harvesting. The company is completing the first phase of its production facility. MYM Nutraceuticals’ planned extraction and processing department there will also house a cannabis product testing and research laboratory in partnership with TheraCann Canada – a leading ISO compliance testing firm.
  • Casino, South Wales, Australia: The Northern Rivers Project is a co-venture just reached between PUF Ventures and MYM Nutraceuticals for a 35% stake in a proposed 1.2 million square foot greenhouse and extraction facility in Casino, New South Wales, Australia. At full scale, the facility will have the capacity to produce 100,000 kilograms of high quality cannabis per year, worth between C$800 million and C$1.1 billion.
  • January 2018, MYM Nutraceuticals announced it signed a Memorandum of Understanding (MoU) with NEWCANNA S.A.S., a leading Colombian medical cannabis company for a joint venture or partnership agreement in which they would form a new, jointly owned company in Colombia to focus on the large-scale commercial cultivation and transformation of cannabis and hemp for medical, scientific and industrial purposes and export to worldwide markets.

Deloitte Review Of Weedon Facility

Unlike many companies entering in this budding new area, MYM Nutraceuticals has a very clear view of its prospects. A case in point is the Deloitte Report on the company’s Weedon facility that gives a great breakdown of the its flagship project in Quebec, Canada.

Report Highlights

  • Fixed assets investments: Investments of $104 M are planned for the construction of cannabis production greenhouses in Weedon, Québec, as well as $119 M for the construction of a multipurpose center, which will include a museum, an auditorium, a cafeteria, a school, a restaurant, a bookstore, a luxury hotel, a clinic and a cannabis research and innovation center. These two infrastructures represent a total of $223 M in construction investments.
  • Total economic impact: The total economic impact (added value to the project’s costs) for all construction projects and greenhouses operations on a 15-year period, assuming full production capacity, is estimated at $3.1 B for Canada. The breakdown goes as follows: $208.1 M for construction and $2.9 B for operations ($194.9 M per year). As for Québec, using the same calculation method, the economic impact over the same period of time is estimated at $2.2 B.
  • Economic impact generated by the construction: The direct value added to GDP from the construction projects in Canada is estimated at $93.1 M and the total impact (including indirect and induced impacts) is estimated at $208.1 M. The economic impact in Québec is estimated at $173.5 M.
  • Economic impact generated by the operations: The total economic impact in Canada of the greenhouses operations (including indirect and induced impacts) generated by the operating expenses is estimated at $2.9 B for a period of 15 years, or $194.9 M per year. The economic impact for Québec is estimated at $2.1 B for the same period.
  • Governments Tax Revenues: The construction projects and the greenhouses operations will generate tax revenues (excluding corporate taxes and potential excise duty) of nearly $493.4 M for the Government of Québec and nearly $277.6 M for the Government of Canada.

So in essence, the company’s Weedon facility represents  a $2.9 Billion (CDN) operation annually upon completion.

Conclusion: Recreation legalization will create a brand new wave of investment opportunity. While established companies that started with medical brands are trying to address the upcoming recreational market through acquisitions and capacity expansions, companies entering the recreational market directly like MYM Nutraceuticals will have a distinct competitive advantage given their recreational-ready business model.

MYM Nutraceuticals’ approach is one of our favorites in the emerging rec market thanks their impressive investment highlights.

For investors looking to get into the huge potential of the recreational market with an up and coming company that’s not already valued like a big board stock,  small cap company, MYM Nutraceutical (CSE: MYM) (OTC: MYMMF) could be a great option.

 

Editorial Staff

Canada News Group

 

Disclaimer: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of Canada News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment

These Are The Best Paying, Most Satisfying Jobs In The UK

If you’ve come back to work after Christmas feeling a little disillusioned with your job, then don’t worry – it’s entirely natural. After all, give most people the choice between sitting on their parents’ couch eating sausage rolls and looking at spreadsheets on a computer, and there’s only going to be one winner.

If your feelings of disillusionment extend beyond sausage roll nostalgia though, then perhaps it is time to start thinking about pastures new. We live in a world where millennials (that’s probably you) do not expect to stay in a job for much longer than three years. And with so many exciting new roles created every day by our fast-evolving technological world, why would you want to?

But where to focus your efforts? Luckily, Glassdoor, one of the world’s biggest job sites, has published its annual report on the best jobs out there. How do they decide whether something is the “best” job? Well, it’s based on three factors: earning potential, job satisfaction rating and the number of job openings. This year, for the first time, not one tech-based role features in the top 10.

The so-called “best” job, then? Glassdoor is calling it – “Marketing Manager”. With an average job satisfaction rating of 4.0 (out of 5), a median base salary of £42,000 and 1,580 openings currently listed on site, it doesn’t sound too shabby.

In second and third space come “Operations Manager” and “Audit Manager” with satisfaction ratings of 4.0 and 4.3 respectively. Operations managers can enjoy a median base salary of £42k and an audit manager £55k.

Working our way down the list, the great jobs continue. In fourth place we find “Finance Manager” (job satisfaction 3.6, median base salary £60,900), fifth place is “Product Manager” (3.7 and £52,000) and sixth place belongs to “HR Manager” (4.2 and £45,750).

“Although tech jobs don’t make the Top 10 this year, jobs in finance and other more highly skilled traditional roles remain prominent in the UK,” said Dr. Andrew Chamberlain, Glassdoor’s chief economist. “However, this year will see AI and job automation impact every facet of the UK workforce in some way, and two industries that are ripe for considerable changes in 2018 are human resources and finance.”

He continued: “Revolutionary new AI tools are complementing people’s skills in both these industries, which could upend many established and easy-to-automate roles that we see in this list.”

Here’s the list in full.

The 25 Best Jobs In The UK

1. Marketing Manager – 4.0, £42,000
2. Operations Manager – 4.0, £42,000
3. Audit Manager – 4.3, £55,000
4. Finance Manager – 3.6, £60,900
5. Product Manager – 3.7, £52,000
6. HR Manager – 4.2, £45,750
7. Contract Manager – 4.0, £40,000
8. Commercial Manager – 3.8, £52,400
9. Business Analyst – 3.7, £52,400
10. Project Manager – 3.5, £44,000
11. Business Development Manager – 3.7, £38,000
12. Software Engineer – 3.5, £42,500
13. HR Business Partner – 3.8, £55,000
14. Solutions Architect – 3.5, £70,000
15. Production Manager – 3.8, £35,000
16. Data Analyst – 4.0,£28,500
17. Data Scientist – 3.6, £45,000
18. Communications Manager – 3.9, £45,000
19. Recruiter – 4.1, £25,000
20. National Account Manager – 4.2, £45,000
21. Site Manager – 3.5, £35,750
22. Mobile Developer – 3.8, £50,000
23. Brand Manager – 4.0, £40,000
24. Engagement Manager – 4.2, £55,000
25. Executive Assistant – 3.9, £36,000

A merger of two of the biggest players in Potash has sparked investor interest in the fertilizer market.

There are two sides to this story, since MOP (The common form of potash that is currently over supplied and underperforming), SOP (the non-chloride form of potash) commands a hefty premium and is now in high demand.


We reviewed the current shift in the potash industry and discovered that Potash Ridge Corp. (OTC: POTRF / TSX.V: PRK), a junior resource company, is uniquely positioned to become the smart value player in the premium potash segment. The company is pouring all of its resources into its Blawn Mountain prospect in Utah, which stands to make Potash Ridge the lowest cost producer in the market. 


Investors looking to take advantage of the situation will see why we are big on Potash Ridge.

The world is continually losing its supplies of arable land that can be used to produce food. We can argue why it’s happening – climate change, crop saturation, urbanization and many other factors – but the reality is that it is happening, and fast.

In fact, Earth has lost a third of arable land in past 40 years, scientists say. (1)

At the same time, the world’s population continues to boom. Over the next three years, we can expect there to be 7.7 billion people on the planet. (2)

That’s a lot of mouths to feed.

These are not new problems, but they do require new solutions to help feed the billions of people who rely on just a few regions to supply food.

The simplest and most widespread solution is the use of fertilizers. These can increase crop yield and provide higher quality food products with less defects. They can also bring down the cost to produce food.

Of the leading fertilizers, potash is a vital answer.

Potash is a generic term that refers to a group of potassium-bearing minerals, naturally occurring potassium salts and the products produced from those salts.

Here’s why potash is so important:

Potash is a plant’s main source of potassium. It is one of the four primary nutrients required for plant growth. The remaining three nutrients are Nitrogen, Phosphate and Sulphur.

Potash is used as a highly effective fertilizer routinely in the major food and crop growing regions especially China, Brazil and North America.

While potash is widely available –there is currently enough over supply to have the major producers of Muriate of Potash (MOP) close plants in order to limit supply imbalances – the more specialized Sulfate of Potash (SOP) is in more in demand than ever, with very few supply sources.

This is the basis for an excellent opportunity to leverage SOP resources in a big way.

Consider Potash Ridge as one of the only pure SOP potash plays in North America. See Our Recommendation.

Not All Potash is Equal

There are two forms of potash, both used as fertilizer, but differentiated by their makeup and pricing model.

Muriate of Potash (MOP) also known as Potassium Chloride (KCI), is widely used in all types of farming, but contains a chloride ion that can be detrimental towards plant growth, especially fruits and vegetables.

If the chloride content isn’t managed, it can lead to low quality crops and inhibit place growth in dry soils and saline areas.

Sulphate of Potash (SOP) is the most commonly used non-chloride potash fertilizer in the world, with an annual worldwide demand of 6 million short tonnes per year (3).

It can be sold as a powder for use in compound fertilizers containing nitrogen, phosphate, potassium, and sulphate, as a granular product for direct application, or as a soluble product for use in fertigation.

SOP is priced at a premium to MOP, and is utilized for sensitive, high-value crops including many fruits, vegetables, tobacco and tree crops such as nuts.

China is the largest consumer and producer of SOP with the total demand of 43%.

In China, the use of SOP is driven by a significant tobacco production as it is the largest tobacco producer in the world.

China is the main exporter of SOP fertilizer and has a production capacity of approximately 4 million tonnes.

Broad Market for Potash Shows Stable Growth Solid

In late 2017, the largest producer of potash, PotashCorp of Saskatchewan, Canada proposed a merger with one of the other largest producers, Agrium, Inc.

Analysts see the merger as a move to galvanize the marketplace.

According to PotashCorp, the demand for potash and the strength in global demand will continue this year. It’s expected to be 62 million–65 million tons in 2017, which will be up from ~60 million tons in 2016.

Potash prices have bounced back stronger too.

Granular potash prices in Brazil have risen as much as 17% YoY (year-over-year) to $274 as of October. In the US Corn belt region, prices have risen ~5% YoY. The standard grade of potash was also 5% higher YoY in the South East Asia region.

The global Potash Fertilizers Market is expanding with considerable growth potential during the next five years.

PotashCorp projects anywhere between 2.5% and 3% CAGR in potash consumption.  (4)

The wide potash market has pulled back since its highs prior to 2008, mostly due to over production.

Still, demand for the mineral is growing and the major producers have managed to help bring pricing in line with demand by limiting production.

Our research shows that the SOP segment is a quiet performer that’s being largely ignored within the potash space.

SOP Is the Premium Product Potash Ridge Plans to Produce in the US

Potash Ridge is a junior resource company based in Toronto, Canada.  It holds two highly de-risked and advanced development stage potassium sulphate (SOP) projects; the Blawn Mountain Project in Utah, and the Valleyfield project in Quebec, Canada.

Potash Ridge just announced plans to spin-out the Valleyfield project into another public company in order to create greater value and focus its efforts on the development of its proposed 255,000 ton per year project at Blawn Mountain.

This will provide Potash Ridge with further value and the ability to apply all of its resources to its Utah assets.

The Blawn Mountain Project is comprised of four areas of alunite mineralization covering approximately 11,550 acres of land owned by SITLA (State of Utah School and Institutional Trust Lands Administration) near Milford, Utah.

State-owned land provides Potash Ridge with several advantages including a simpler permitting process, leasehold and royalty agreements in place and no environmental, social or aboriginal issues.

Most importantly, the Blawn Mountain project has the support of both the municipality and state.

The region has all the necessary infrastructure to support in place to accommodate the development of the Blawn Mountain Project, including nearby highway and rail access.

Extensive development was completed on the leases in the 1970s including a mine plan, feasibility study and 3-year pilot plant operation.

A prefeasibility study in 2016 showed Blawn Mountain to have proven and probable mineral reserves of 153 million tons; reserves that support a 46-year project life with an average of 255,000 tons of potassium sulphate per annum during first 10 years of operation after ramp-up.

Potash Ridge plans to extract alunite – the potash mineral –through surface mining operations, considered much lower-cost and lower-risk than underground mining operations.

Potash Ridge To Be North America’s Lowest Cost Source of SOP Potash

There are two methods used in the production of SOP.

Primary production methods include directly extracting SOP from mineral ores containing both potassium and sulphate.

This method is currently fairly rare and may yield by-products, which can contribute additional revenue.

Potash Ridge plans to use this method of production at the Blawn Mountain Project.

The most common secondary production method is referred to as the Mannheim Process and involves the reaction of KCI with sulphuric acid.

This method for producing SOP accounts for 50% to 60% of the global production.

The Mannheim Process is the most expensive method of producing SOP due to energy requirements and high cost of purchasing MOP and sulphuric acid.

Potash Ridge will rely on direct extraction methods to become the lowest cost producer of premium SOP in North America.

Using this approach, Potash Ridge expects to produce from its Blawn Mountain prospect for about $250 per tonne all in. That’s compared to an industry average cost to produce SOP of roughly $550 per tonne.

This is a huge advantage for Potash Ridge.

There’s No Such Thing as a Sure Thing

Somethings are inevitable, besides death and taxes. These include the rising population and the need to feed people. For that reason, we really like the potash space and Potash Ridge’s approach.

The companies that sell MOP will continue to see predictable prices through production controls and increases in market demand. The industry CAGR of around 3% is reasonable, and there will likely be upward movement as the big players join forces in the M&A game.

But there’s another side to the potash market and that’s where we see Potash Ridge leaping ahead. It’s also where early investors can look for rewards by getting ahead of market moves.

Potash Companies Are On the Move with Large Players Merging Forces to Fortify Their Position. For Significant Returns in Potash, Investors Will Need to Dig Deeper – See Our Recommendation

FEATURE STOCK: FOR COMPARISON

Potash Ridge

OTC: POTRF // TSX.V: PRK

Market Cap: $21.617 million

Potash Ridge Corporation explores, develops, and produces mineral properties in North America. The company explores for alunite deposits to produce sulphate of potash, sulphuric acid, and alumina. It principal mineral project is the Blawn Mountain project covering an area of approximately 15,403 acres of land located in Beaver County, Utah. Potash Ridge Corporation was incorporated in 2011 and is based in Toronto, Canada. 


Potash Leaders: Big Gains Already Built in, But Good Models to Study

We’ve offered a few of the leading potash companies who dominate the potash space. These stocks represent some of the largest and most mature potash companies who have already experienced initial growth, so those milestones are built in to their prices. It’s unlikely they will achieve the kind exponential growth that our feature company could produce, but they are great models for solid growth and well managed potash players.

Potash Corp.

NYSE: POT // TSX: POT

Market Cap: $16.25 million

Potash Corporation of Saskatchewan Inc., together with its subsidiaries, produces and sells fertilizers, and related industrial and feed products worldwide. It operates in three segments: Potash, Nitrogen, and Phosphate. It owns and operates five potash mines in Saskatchewan and one potash mine in New Brunswick. The company was founded in 1953 and is headquartered in Saskatoon, Canada.

Recent Headline: Where Potash Fertilizers Are Headed in the Near Term

The Mosaic Company (MOS)

NYSE: MOS //

Market Cap: $8.41 billion

The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients worldwide. The company operates through three segments: Phosphates, Potash, and International Distribution. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant, as well as fluorosilicic acid for water fluoridation. The Mosaic Company was founded in 2004 and is headquartered in Plymouth, Minnesota.

Recent Headline: Mosaic To Present At Upcoming Investor Conference

Compass Minerals International, Inc.

NYSE: CMP

Market Cap: $2.356 million

Compass Minerals is a leading provider of essential minerals that solve nature’s challenges, including salt for winter roadway safety and other consumer, industrial and agricultural uses, and specialty plant nutrition minerals that improve the quality and yield of crops. The company produces its minerals at locations throughout the U.S., Canada, Brazil and the U.K.

Recent Headline: Compass Minerals Declares Dividend

Agrium Inc.

NYSE: AGU TSX: AGU

Market Cap: $14.89 million

Agrium Inc. produces, markets, and distributes crop nutrients, crop protection products, seeds, and merchandise products primarily in the United States, Canada, Australia, and South America. It operates in Retail and Wholesale segments. The company was formerly known as Cominco Fertilizers Ltd. and changed its name to Agrium Inc. in 1995. Agrium Inc. was founded in 1931 and is headquartered in Calgary, Canada.

Recent Headline: Agrium and PotashCorp Announce Mailing of Letters of Transmittal and Election Forms to Registered Shareholders in Connection with Merger of Equals Transaction


 Our Recommendation: Potash Ridge Gets Our Strong BUY Rating

Potash Ridge is completely focused on its SOP production at Blawn Mountain in Utah. At production, Potash Ridge will be one of the only producers of SOP in the United States, and potentially the only one using their direct extraction method from surface mining.

They have the opportunity to be North America’s lowest cost producer.

We think that puts them way ahead of the curve, having the foresight to position for increases in demand of SOP.

We also really like the fact that the company has established itself as a pure-play SOP potash company with a 100% domestic property in a mining-friendly jurisdiction. Utah is the perfect home for SOP development.

To Review: Here is Why Are Bullish on SOP and Potash Ridge

There is massive opportunity right now in the uncertainty of this market, and we expect the fundamentals to be re-balanced in the near-term.

MOP fundamentals might take a bit to rebalance as the global supply-demand picture vacillates. For our readers, that’s a positive.

We are confident that the premium-priced potash, SOP, is an emerging winner, which gives us reason to focus on junior resource companies, particularly Potash Ridge.

This company has a strong asset base with real promise for the long-term development of a much needed product. Here’s what we think makes SOP a winner:

  • SOP markets have very attractive pricing
  • There is a significant supply deficit on the SOP side
  • SOP has a limited new production pipeline
  • SOP demand is growing rapidly in world markets

Potash Ridge stands to leverage its position:

  • the lowest cost producer in North America
  • located in a mining friendly jurisdiction
  • focused on serving California market with soluble SOP
  • initial production rate of 255,000 tons per year
  • 45+ years proven and probable reserves
  • all permits and water rights secured for Blawn Mountain
  • all infrastructure within 30 miles
  • well-funded and already to advance
  • capable management with proven ability to bring projects to production

While MOP might be experiencing a glut right now, that is expected to soon be rebalanced. Couple that with the fact that supply for SOP is tight, and the margins for SOP become increasingly attractive, creating a great spot for juniors breaking into a high-reward versus risk opportunity.

Potash Ridge is poised to be the premier producer of SOP in North America in the next several years. We believe that early investors getting ahead of the rise of in demand of potash supplies will see the biggest gains.

** Note **

As mentioned, Potash Ridge is in the lucrative SOP segment of potash, which is vastly different from competing with the majors to produce lower price MOP segment of potash. We are impressed by their determination to bring on the premium product and become a leading supplier. They’re well-funded and moving swiftly.

This is the kind of opportunity investors look for, but often let pass by because it’s “not sexy enough”. Don’t let the potash window dressing fool you. This thing has legs.

USA News Group

Editorial Staff

 

 

Sources:

(1)https://www.theguardian.com/environment/2015/dec/02/arable-land-soil-food-security-shortage

(2) https://www.potashcorp.com/overview/fertilizer-101/global-development-story/global-population-arable-land-per-capita

(3) Report Text: (Global SOP Market: Trends & Opportunities (2013-2018) – https://www.scribd.com/presentation/176494443/Global-Sulfate-of-Potash-SOP-Fertilizer-Market-Trends-Opportunities-2013-2018-Daedal-Research

(4) https://marketrealist.com/2017/12/outlook-potash-fertilizers-headed-near-term/

(5) Potash Corp: https://potashcorp.com

(6) The Mosaic Company: https://mosaicco.com

(7) Compass Minerals: https://compassminerals.com

(8) Agrium Inc.: https://agrium.com

(9) Potash Ridge: https://potashridge.com

 

 

Disclaimer

 

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

 

Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.

 

Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Potash Ridge advertising and digital media from the company. There may be 3rd parties who may have shares of Potash Ridge, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group owns shares of Potash Ridge that were purchased in the open market and will not sell any shares in the next 72 hours from the publication date (Dec. 5, 2017), at which point we reserve the right to buy and sell shares without any further notice.

 

By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing MIQ, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

Like It Or Not, The Cannabis Sector Is Unstoppable, And It’s Just Getting Bigger

Many U.S. investors are seeking ways to invest in the emerging cannabis space, but think they may have missed out on the green rush. There are still prime opportunities to get in on pure cannabis plays right now. The profits in this space could be almost obscene for some companies and one in particular is poised to become the next giant. We break down MYM Nutraceuticals (CSE: MYM; OTC: MYMMF) and its exceptional efforts that are already paying off.


It’s sometimes hard to see the big picture. In the cannabis space, there is so much activity taking place right now that investors may feel a little overwhelmed. It’s no wonder… what with the chorus of Cannabis companies entering production and even the legislation governing cannabis’ use changing before our very eyes.

One thing is crystal clear: this is the age of opportunity for Cannabis and its investors. Just take a look at the projected growth following legalization of pot in Canada: (1)

That’s not to mention the global markets, including the growing legalized medical market in the United States.

If you’ve been through the rise of an emerging market like the early internet or the arrival of mobile technology, you know just how incredibly lucrative these situations can be. If not, prepare yourself for a wild ride.

Several major factors are about to set the Cannabis market on fire:

  • Legalization of Recreational Cannabis in Canada
  • Major funding from legitimate financial sources supporting global growth
  • Sophisticated research yielding scientific results validating Cannabis’ medicinal value
  • Professional business practices applied market wide

Based on these imminent events, several companies will expand at a near exponential rate, becoming long-term fixtures in the Cannabis industry and making many investors very wealthy.

We’ve singled out MYM Nutraceuticals (OTC: MYMMF) (CSE: MYM) as a lead contender in the Cannabis space based on its series of early achievements and the rapid pace of its advances. In the next stage of development, MYM is set to become the proverbial Next Big Thing.

Watch this short video to see some of the impressive projects MYM is currently working on:

You Could Get in on the Next Cannabis Giant Before the Street. See Our Recommendation:

MYM Nutraceuticals: The Next Cannabis Giant in the Making

In the cannabis market there are mostly big companies and small companies. The small companies are quickly striking deals and rolling up into the big ones. The big companies are becoming giants. That’s exactly the vantage point of our feature company.

MYM Nutraceuticals Inc. is a well-positioned Cannabis company that’s been taking an integrated approach to the Cannabis market with a serious long-term perspective. In little over a year, the company has transformed its entire business and is on the path to becoming Canada’s largest producer of Cannabis.

That’s just for starters.

MYM has also become a leading integrated provider of branded products related to the natural cannabis nutraceuticals industry. This strategy, coupled with its strategic partnerships, international expansion and growth in revenue have vaulted MYM Nutraceuticals to a whole new league.

The Massive Cannabis Market Ahead

Based on the lead call by Canada’s Prime Minister, Justin Trudeau this year to introduce legislation that will legalize recreational cannabis by July 2018, that country is gearing up for huge demand not previous seen. (2)

Researcher Deloitte expects that Canada’s legal weed market will grow to about CDN$8 to CDN $10 billion by 2025, not counting support and ancillary services. At that point, it will be larger than Canada’s market for alcohol. (Note)

This news has set Canada on a mission to quickly expand all current Cannabis operations and add new Licensed Producers as quickly as possible. The government is pushing for even more new licenses to accommodate growth.

Outside of Canada, the global market is also exploding.

Demand has grown dramatically in the U.S., Europe and Australia among licensed medicinal jurisdictions. According to researchers at New Frontier Data, they project that the cannabis industry will have created a whopping 283,422 jobs, grow to and generate $2.3 Billion in tax revenue—both by 2020.

The same study predicts that the sector as a whole will grow to $24.1 Billion by 2025. (3)

The cannabis market is a rolling juggernaut, producing a massive demand that shows no signs of slowing.

MYM on the Fast Track to Become the Single Largest Cannabis Producer

Through its subsidiary, Sublime Culture Inc., MYM Nutraceuticals (OTC: MYMMF) (CSE: MYM) is in the last stages of obtaining License Producer status under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).

MYM Nutraceuticals has taken a brilliant tact to assemble what, upon completion, will be the largest group of Nutrient growing facilities in the world. The company has three projects that will bring its total growing capacity to over 625,000 square feet as early as 2019.

The projects include:

Weedon, Quebec: Its flagship project is a planned 1.5 million square foot growing facility in the town of Weedon, Quebec. Through its subsidiary, CannaCanada, the company is building what will be, at full capacity, the most productive Cannabis facility in the world by total output.

In its initial phase, the 300,000 square foot phase 1 will produce up to 30,000 kilograms of cannabis per year.

The facility has received whole-hearted endorsement by the local government in Weedon, which has reached a first-of-its-kind arrangement, whereby the city will provide the large land lease for the mega-facility in a co-venture with MYM Nutraceuticals. Weedon will provide MYM with 329 acres to expand on.

Laval Quebec: is a smaller by comparison, but will be MYM Nutraceuticals’ first operation to come online and begin harvesting. The company is completing the first phase of its production facility by the end of 2017. MYM Nutraceuticals’ planned extraction and processing department there will also house a cannabis product testing and research laboratory in partnership with TheraCann Canada – a leading ISO compliance testing firm.

Casino, South Wales, Australia: The Northern Rivers Project is a co-venture just reached between PUF Ventures and MYM Nutraceuticals for a 35% stake in a proposed 1.2 million square foot greenhouse and extraction facility in Casino, New South Wales, Australia. At full scale, the facility will have the capacity to produce 100,000 kilograms of high quality cannabis per year, worth between C$800 million and C$1.1 billion.

As with its Weedon project, MYM Nutraceuticals has invested with local government (PUF Australia is a government backed venture) to ensure its stability. (4)

Diversifying by Integrating Brands, Testing, R&D and Distribution

MYM Nutraceuticals is also diversifying across some the most lucrative cannabis segments.

High-margin Cannabidiol or CBD nutraceuticals is one of the fasted growing sectors in the medical cannabis industry and is expected to capture an early majority share of the global cannabis market.

Clinical research studies have demonstrated that CBD nutraceuticals have the potential to treat arthritis, MS, chronic pain, PTSD, depression, epilepsy and a myriad of other illnesses and disorders.

This is the major area for MYM Nutraceutical’s branded products. The company’s focus is developing high-end, organic medicinal marijuana supplements and topical products; hence the title nutraceuticals. These are products with safe, natural approaches to many different conditions or ailments not served by other products.

In its relatively short lifespan, MYM Nutraceutical has established multiple subsidiaries with products marketed under the Joshua Tree, MyHemp Skin Therapy, HempMed and Dr. Furbaby brands.

These companies develop and sell a variety of products including custom-made cannabis products with tailored CBD chemistries along with tinctures, concentrates and oils, edibles, vape products and pet care products carried by 74 retailers across Canada and online.

MYM Nutraceuticals also boats first-in-class R&D in developing the highest quality cannabis-based nutraceuticals.

The company’s planned extraction and processing department will house a cannabis product testing and research laboratory in partnership with TheraCann Canada, considered the “gold standard” in approved cannabis testing in Canada.

Own the Next Major Canadian Cannabis Stock While It’s Still Under the Radar. See Our Recommendation.

Get Really Big Really Fast or Get Bought

It’s evident that the Cannabis market is undergoing a major maturation process. Whether recreational legalization in Canada falls in place by te self-imposed July 2018 deadline or not, a select group of producers  will become massive operations, growing thousands of kilograms of Cannabis annually to meet the legal demand.

MYM Nutraceuticals is in the slot to become one of the elite.

With maturity will come competition, and of course a lowering of prices. That’s typically followed by the obvious shake out that brings the best companies in line with the market. When that takes place, diversification will be a major differentiator.

In MYM Nutraceuticals favor, the company will likely be big enough and well diversified so as to be one of the players grabbing up the nascent cannabis companies or brands. That’s a simple way for MYM to expand its roll up and further its market lead in Canada and international markets.


FEATURE STOCK: FOR COMPARISON

[table id=24 /]

The Winners: Already Huge Gainers, Well Worth the Study

There have been some very big winners in the cannabis market this year. It would be hard to point out a single company, so we have selected the market’s elite group. These are the leading Canadian companies that analysts expect to become major fixtures of the industry. We point to them here as shining examples of the explosive potential for growth and profits in this emerging sector.


[table id=25 /]

Our Recommendation: MYM Gets Our Strongest BUY Rating

It is easy to get caught up in all the hype surrounding the cannabis market and get distracted. We have focused instead on important milestones by a company building a proven track record for successes.

Of the many cannabis companies we’ve come across over the last year, none of them to date have shown the kind of potential evident in MYM Nutraceuticals at such an early stage.

Just to recap, here’s what MYM has accomplished in an extremely short time period:

  • Negotiated three major agreements for growing facilities at Weedon and Laval, Quebec alongside Casino, Australia.
  • On track for total growing capacity of about 1.7 million square feet in Canada and 1.2 million square feet in Australia.
  • Launched it Quebec growing operation slated to begin with first harvest anticipated by end of 2017
  • Readied Phase two expansion at Laval, including extraction, R&D and product testing facility to begin in early 2018.
  • Kicked off revenue generation with branded products from sales projected to reach $2million this year.
  • Reached strategic partnerships with leader TheraCann Canada, PUF Ventures and others.
  • Established strong brand recognition and a network of global distribution channels.
  • Expanded to international markets with the addition of its Australian facilities and partners.
  • Secured financing to meet or exceed all immediate expansion needs into 2018.

All of these critical advances have come to fruition in little more than a year.

We suspect that has only been possible because of MYM Nutraceuticals’ experienced management group who have more than over 40 years of medical marijuana experience.

Canada’s Prime Minister Justin Trudeau calls for the legalization of recreational marijuana by July 1, 2018.


Investors Need to Position Themselves Right Now. Here’s Why:

For investors looking for a direct way into the cannabis market, or simply catch the next major upswing in cannabis, this is a simple, direct path.

MYM Nutraceuticals is a pure cannabis play, working hands-on with all aspects from growth through formulation, testing and branded products. And it has a wide open pathway to assume a leading role in this industry.

The company has been able to use the momentum of the cannabis rush to leverage its early position and has what it takes to create a sustainable model. It has made multiple key acquisitions and negotiated major strategic partnerships in its bid to create a totally integrated production, formulation, and marketing and distribution company.

We are convinced that the Cannabis market holds untold opportunity at the moment and MYM Nutraceuticals’ time to shine has arrived.

Note: We can’t emphasize enough the fact that investors in MYM Nutraceuticals are getting in on a public company, which provides liquidity and a solid exit strategy. It also means that the company’s value is reflected in milestones in revenue, earnings and its potential measured against its peers.

 

USA News Group

Editorial Staff

 

 

Sources

(1) https://www.huffingtonpost.ca/2016/10/27/marijuana-legalization-market-size-canada_n_12676754.html

(2) https://www.newsweek.com/canada-marijuana-laws-legalization-justin-trudeau-581971

(3) https://newfrontierdata.com/marijuana-insights/legal-cannabis-market-growth/

(4) https://www.prnewswire.com/news-releases/mym-enters-partnership-to-build-one-million-square-foot-cannabis-production-facility-in-australia-300538765.html

 

 


 

 

Disclaimer: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment

Billionaire Founder Of Virgin Group Richard Branson Is Pro Cannabis, And For Good Reason

Not since the time of the ‘Tech Bubble’ have investors seen opportunities like the ones we are experiencing right now, and the good news is… This is no bubble, it’s a revolution!

There’s plenty of more information below (Including a link with a major breakdown of this company), but to start, watch this short video and see why MYM Nutraceuticals (OTC: MYMMF / CSE: MYM) is our #1 growth pick for the Cannabis Sector, period!



Unlike Blockchain (Bitcoin), and a handful of other sectors that are ‘hot’ right now, the Cannabis sector does not have an unclear future; it’s 100% fact, like it or not, Cannabis, (recreational and its vast medicinal uses) is literally in its infancy, and this sector is gearing up to be the biggest thing you will likely see in your lifetime.

Here’s the best part: The biggest rise is yet to come.

We’ve reviewed dozens of cannabis related stocks, and unlike most that are just trying to cash in by riding the Cannabis wave, we’ve isolated what we believe to have the most potential going forward in this sector.

At MYM’s current price, some might consider this an opportunity similar to buying Amazon (AMZN) back in August 1997 when it was trading for only $4.34 / share (Yes the Cannabis space could very easily be this big, if not bigger). MYM is just getting started, and some smart investors, the kind that can see what’s about to happen here, are just starting to take notice.

This is a virtually undiscovered company when you consider the facts, and MYM is rising through the ranks and is poised to become the next major producer of Cannabis in Canada, and Worldwide.

Still unsure about the marijuana boom? Read our in-depth report here…

Canadian Cannabis Companies Are Leading The Way And The Domino Effect That Will Follow Is Going To Be Unprecedented!

 

Here’s The Top 3 Reasons to Get In On the Cannabis Boom Before 2018 Sends Pot Stocks Soaring To New Highs:


1)
Canada is one of just a handful of countries around the world to have legalized medical cannabis all the way back in 2001. Because medical weed is legal, publicly traded companies are able to generate growing sales and profits just from the medical side of the equation.

This is a unique situation that is making marijuana stocks incredibly valuable, just wait until ‘Big Pharma’ get their hands on this Sector! Only those companies positioned like MYM will see massive, massive gains.

2) There’s a very real possibility that Canada will become just the second country in the world after Uruguay, and the first developed country, to legalize recreational marijuana in 2018.

Canadian Prime Minister Justin Trudeau introduced legislation in April that would allow people aged 18 and up to buy weed legally by July 1, 2018. The government has also just outlined tax plans that would offer a lower tax rate on marijuana than on alcohol in Canada.

Trudeau has indicated that a low tax rate is needed to make pot price-competitive with black market marijuana, reducing the competition between the two, while maintaining proper quality control.

3) The major producers of weed stocks, almost without exception, have been consistently profitable.

Canopy Growth was profitable through the first three quarters of fiscal 2017 and only lost money for the year because of acquisition-related expenses. Aphria produced a full-year profit in fiscal 2017. The other large producer, MedReleaf, has been consistently profitable for the past two years.

Producers of cannabis have turned the corner and are on track for major profits as they invest in massive expansion across the Globe.

If you are like most investors, you can no longer ignore the rapid growth rate of marijuana stocks. The upcoming year could be the ideal time for aggressive investors to consider adding this sector to their portfolios.


STILL NOT CONVINCED? WANT TO KNOW MORE ABOUT MYM NUTRACEUTICALS AND ITS MARKET CHANGING DEVELOPMENTS? CLICK HERE

 

// Staff Editor, USA News Group


Sources:

  1. Business Insider: https://www.businessinsider.com/richard-branson-supports-legalizing-marijuana-health-problem-not-criminal-2016-11
  2. Financial Post: https://business.financialpost.com/commodities/agriculture/justin-trudeaus-liberals-to-introduce-legislation-to-legalize-marijuana-by-2018-cbc-reports
  3. The New York Times: https://www.nytimes.com/2017/07/19/world/americas/uruguay-legalizes-pot-marijuana.html
  4. MYM Nutraceuticals: https://www.mymarijuana.ca/presentation-video/
  5. Global News: https://globalnews.ca/news/3378603/marijuana-laws-around-the-world/
  6. Forbes: https://www.forbes.com/sites/julieweed/2017/11/26/california-weed-entrepreneurs-will-make-5-2b-in-2018-with-almost-no-banks-to-put-it-in/
  7. The Star: https://www.thestar.com/business/2017/11/14/canopy-growth-reports-13-million-loss-despite-doubling-its-revenue.html
  8. Aphira Inc. (Press Release): https://www.marketwired.com/press-release/aphria-records-fifth-consecutive-quarter-of-profitability-tsx-aph-2209637.htm
  9. Midas Letter: https://www.midasletter.com/podcast/medreleaf-corp-ceo-neil-closner-growing-best-marijuana-canada/

 

 

Disclaimer:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. usanewsgroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for MYM Nutraceuticals advertising and digital media. There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of USA News Group has purchased a total of two thousand shares of MYM Nutraceuticals in the open market and own an additional five hundred and fifty five five hundred and fifty five thousand shares purchased through a subscription agreement (along with a corresponding amount of warrants exercisable at .40 starting October 3, 2017) and have no plans on selling these shares in the next 72 hours (from June 19, 2017) but reserve the right to buy and sell shares in MYM Nutraceuticals, Inc. at any point after June 22, 2017 – No further notice shall be given.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment